Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001205544 | SCV001376806 | uncertain significance | Neurofibromatosis, type 1 | 2019-09-16 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine with valine at codon 2155 of the NF1 protein (p.Ile2155Val). The isoleucine residue is moderately conserved and there is a small physicochemical difference between isoleucine and valine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with NF1-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV002365923 | SCV002656893 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2021-12-23 | criteria provided, single submitter | clinical testing | The p.I2155V variant (also known as c.6463A>G), located in coding exon 42 of the NF1 gene, results from an A to G substitution at nucleotide position 6463. The isoleucine at codon 2155 is replaced by valine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |